Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Quest Diagnostics Incorporated, a leading name in the medical laboratories industry, is headquartered in the United States. Founded in 1967, the company has established itself as a pivotal player in diagnostic testing and laboratory services, with a strong presence across major operational regions in North America.
Specialising in a wide array of diagnostic tests, including clinical laboratory services and anatomic pathology, Quest Diagnostics is renowned for its commitment to accuracy and innovation. The company’s unique integration of advanced technology and extensive test menu positions it as a trusted partner in healthcare.
With a robust market presence, Quest Diagnostics has achieved numerous milestones, including significant advancements in genetic testing and disease management solutions. Its dedication to improving patient outcomes and enhancing healthcare efficiency solidifies its status as a leader in the medical diagnostics field.
+28 vs industry average
Quest Diagnostics’s score of 54 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medical Laboratories is among the least carbon-intensive industries
The Medical Laboratories industry has reduced its overall emissions by 28% since 2018
Scope 3 accounts for ••• of total emissions.
Quest Diagnostics, a US-headquartered Medical Laboratories company, reported total gross emissions of approximately 738.4 million kg CO2e in 2024. This figure comprises about 103.1 million kg CO2e from Scope 1 emissions, approximately 72.8 million kg CO2e from Scope 2 (market-based), and around 562.5 million kg CO2e from Scope 3 emissions.
In 2023, the company reported total gross emissions of roughly 822.4 million kg CO2e. This included approximately 113.9 million kg CO2e from Scope 1, about 77.5 million kg CO2e from Scope 2 (market-based), and roughly 631.0 million kg CO2e from Scope 3 emissions.
Quest Diagnostics has committed to reducing its Scope 1 emissions by 30% from 2021 levels by 2030. Additionally, the company aims to reduce its Scope 2 emissions by 30% from 2021 levels by 2030.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more